Nutritional support for cancer patients
An Open, Real-world Study of the Effects of Perioperative Intensive Nutritional Management on Short-term Quality of Life and Long-term Life Outcomes in Patients With Multiple Cancers
This study tests whether giving extra nutrition to cancer patients before and after surgery can help them live longer and feel better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1000 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | First Hospital of China Medical University Academic / other |
| Locations | 1 site (Shenyang, Liaoning) |
| Trial ID | NCT06059560 on ClinicalTrials.gov |
What this trial studies
This study evaluates the nutritional status of patients with various types of tumors through continuous nutritional intervention during the perioperative period. It aims to assess the impact of this nutritional therapy on progression-free survival, overall survival, and quality of life. Patients will be monitored and followed up to determine the effectiveness of the intervention in improving health outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 80 with malignant tumors in stages II to IV who are undergoing tumor surgery.
Not a fit: Patients with acute chronic diseases, cognitive dysfunction, or those who are pregnant or lactating may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could enhance survival rates and quality of life for cancer patients undergoing surgery.
How similar studies have performed: While nutritional interventions in cancer care have shown promise in other studies, this specific approach is relatively novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ① Age ≥18 years old, \<80 years old, male or female; ② The patient signed the informed consent and volunteered to participate in the study; ③ Patients with malignant tumors (laryngeal cancer, esophageal cancer, lung cancer, gastric cancer, colorectal cancer, liver cancer, pancreatic cancer) evaluated by clinical stage II to IV; ④ Patients undergoing tumor surgery; ⑤ Patients with NRS 2002 score ≥ 3 after management risk screening; ⑥ Basic reading and communication skills; ⑦ Have the ability to act; Patients with a life expectancy greater than 6 months; Exclusion Criteria: * ① Acute onset of chronic disease; ② Pregnant or lactating women; ③ Patients with contraindications and no tumor surgery; (4) Patients with malignant tumors (laryngeal cancer, esophageal cancer, lung cancer, stomach cancer, colorectal cancer, liver cancer, pancreatic cancer) were confirmed by pathology and/or cytology after surgery; ⑤ Combined with cognitive dysfunction, mental disorder, consciousness disorder or unwillingness to cooperate; ⑥ Patients with severe gastrointestinal symptoms, liver and renal insufficiency (alanine aminotransferase ALT≥2 times the upper limit of normal value; Total bilirubin Tbil≥2 times the upper limit of normal value; Creatinine Cr≥2 times the upper limit of normal value); (7) Patients with two or more types of tumors; Long-term bed rest, hemiplegia or coma; ⑨ Severe dysfunction of liver, kidney and other organs; ⑩ Allergy or intolerance to nutrients or their main components (such as lactose or galactose, etc.).
Where this trial is running
Shenyang, Liaoning
- The First Affiliated Hospital of China Medical University — Shenyang, Liaoning, China (Recruiting)
Study contacts
- Study coordinator: Kai Li, MD
- Email: cmu1h_likai@163.com
- Phone: 8613998245233
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.